PDT Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

PDT Partners’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13,955	Closed	-$98.4K	–	696
2024 Q1	$98.4K	Buy	+13,955	New	+$82.8K	0.01%	606

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

PDT Partners's GLUE Position: Q2 2024 in Review

PDT Partners sold out of Monte Rosa Therapeutics (GLUE) in Q2 2024, closing a stake of 13,955 shares — an estimated $98.4K sold.

PDT Partners first reported a position in GLUE in Q1 2024 and held it in 1 quarter. The position peaked at $98.4K in Q1 2024. 74 funds tracked by Wall St. Rank hold GLUE as of Q2 2024.

PDT Partners reported no remaining Monte Rosa Therapeutics position as of Q2 2024 after selling out during the quarter.
PDT Partners sold 13,955 Monte Rosa Therapeutics shares in Q2 2024, an estimated $98.4K.
PDT Partners first reported a position in Monte Rosa Therapeutics in Q1 2024 and held it in 1 quarter.
PDT Partners's Monte Rosa Therapeutics position peaked at $98.4K in Q1 2024.
74 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2024.

Based on PDT Partners's 13F filing for Q2 2024, filed 15 Aug 2024.